Editas Medicine (EDIT) Current Leases (2019 - 2025)
Editas Medicine (EDIT) posted quarterly Current Leases of $6.0 million for Q4 2025, down 58.84% year-over-year from $14.7 million in Q4 2024, and down 0.94% quarter-over-quarter from $6.1 million in Q3 2025.
Editas Medicine (EDIT) Current Leases (2019 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Current Leases for 7 consecutive years, with $6.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Leases fell 58.84% year-over-year to $6.0 million; the TTM figure through Dec 2025 stood at $6.0 million (down 58.84% YoY), while the FY2025 annual figure was $6.0 million, down 58.84% from the prior year.
- Current Leases fell to $6.0 million in Q4 2025 per EDIT's latest filing, from $6.1 million in the prior quarter.
- Across five years, Current Leases topped out at $18.2 million in Q2 2024 and bottomed at $6.0 million in Q4 2025.
- Historically, Current Leases has averaged $10.7 million across 5 years, with a median of $10.3 million in 2021.
- Annual changes were most pronounced in 2024 — Current Leases soared 76.03% — and 2025, when it sank 66.2%.
- Editas Medicine's Current Leases stood at $10.3 million in 2021, then increased by 7.5% to $11.1 million in 2022, then rose by 9.76% to $12.2 million in 2023, then increased by 20.45% to $14.7 million in 2024, then slumped by 58.84% to $6.0 million in 2025.
- Business Quant data shows EDIT's Current Leases at $6.0 million in Q4 2025, $6.1 million in Q3 2025, and $6.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 6.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.03 Mn |
| Sep 30, 2025 | 6.09 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Mar 31, 2025 | 13.16 Mn |
| Dec 31, 2024 | 14.65 Mn |
| Sep 30, 2024 | 16.39 Mn |
| Jun 30, 2024 | 18.18 Mn |
| Mar 31, 2024 | 12.36 Mn |
| Dec 31, 2023 | 12.16 Mn |
| Sep 30, 2023 | 9.69 Mn |
| Jun 30, 2023 | 10.33 Mn |
| Mar 31, 2023 | 8.33 Mn |
| Dec 31, 2022 | 11.08 Mn |
| Sep 30, 2022 | 11.97 Mn |
| Jun 30, 2022 | 10.15 Mn |
| Mar 31, 2022 | 10.21 Mn |
| Dec 31, 2021 | 10.31 Mn |
| Sep 30, 2021 | 10.26 Mn |
| Jun 30, 2021 | 8.97 Mn |
| Mar 31, 2021 | 7.26 Mn |